ADAP - Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript

Adaptimmune Therapeutics PLC (ADAP) Q4 2020 Earnings Conference Call February 25, 2020 08:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Conference Call Participants Tony Butler - ROTH Capital Kenneth Atkins - Cowen & Company Mohit Bansal - Citi Group Michael Smith - Guggenheim Nick Abbott - Wells Fargo Presentation Operator Ladies and gentlemen, thank you for standing by and welcome to Adaptimmune Conference Call. With that I will turn the call over to Juli Miller. Ma'am you may begin. Juli Miller Good morning and welcome to Adaptimmune's conference call to discuss our full year and fourth quarter 2020 financial results and business update. I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections

For further details see:

Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript